PARP1 and cancer: The increased incidence of lymphopenia and cancer in CKD patients may be due (at least in part) to (i) lengthy, continuous exposure of the cell’s genome to endogenous DNA-damaging compounds and (ii) hypersensitivity to DNA-damaging agents in general as a result of PARP-1 inhibition.